Sapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2-mutated metastatic urothelial carcinoma (mUC).

Joseph W. Kim,Matthew I. Milowsky,Noah M. Hahn,David J. Kwiatkowski,Alicia K. Morgans,Nancy B. Davis,Leonard Joseph Appleman,Sumati Gupta,Primo "Lucky" N. Lara,Jean H. Hoffman-Censits,David I. Quinn,Yu Shyr,Patricia LoRusso,Jeffrey Sklar,Daniel Peter Petrylak

Journal of Clinical Oncology（2021）

引用 6|浏览30

暂无评分

摘要

431Background: A mammalian target of rapamycin (mTOR) inhibitor, everolimus, showed activity in patients with metastatic urothelial carcinoma (mUC) including an exceptional objective response in a ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要